Claims for Patent: 7,998,667

Summary for Patent: 7,998,667

Title:	Mutations of the parkin gene, compositions, methods and uses
Abstract:	The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
Inventor(s):	Brice; Alexis (Paris, FR), Lucking; Christophe (Paris, FR), Denefle; Patrice (Saint Maur, FR), Ricard; Sylvain (Paris, FR), Abbas; Nacer Eddine (Paris, FR), Bouley; Sandrine (Bletterans, FR)
Assignee:	Aventis Pharma S.A. (Antony, FR) Institut National Sante et Recherche Medicale (Paris, FR)
Application Number:	09/856,290
Patent Claims:	1. A method for detecting an autosomal recessive parkinsonian syndrome in a symptomatic subject comprising analyzing a nucleic acid sample obtained from said subject for the presence of one or more heterozygous genetic alterations in a parkin gene comprising SEQ ID NO:1, wherein the presence of one or more heterozygous genetic alterations in said parkin gene indicates that said subject has an autosomal recessive parkinsonian syndrome, wherein said genetic alteration in said parkin gene comprises: a) a heterozygous deletion of any one of the following single exons or exon combinations: exons 2 and 3; exon 2; exons 2, 3 and 4; exon 3; exon 5; exons 3-6; exon 6; exons 6-7; exon 8; exons 7, 8, and 9; or exons 3-9; b) a heterozygous duplication of any one of exons 3, 6, 7 or 11, c) a heterozygous point mutation resulting in any one of the following amino acid changes: Gln34Arg; Asn52Met; Lys161Asn; Lys211Asn; Arg256Cys; Arg275Trp; Asp280Asn; Cys268Stop; Cys289Gly; Arg348Glu; Gly328Glu; or Gly430Asp, wherein said amino acid is encoded by SEQ ID NO:1, d) a heterozygous triplication of exon 2, or e) a combination of a)-d) thereof. 2. The method according to claim 1, wherein said detecting a genetic alteration in said parkin gene comprises isolating nucleic acids from said sample. 3. The method according to claim 1, wherein said detecting a genetic alteration in said parkin gene comprises amplifying nucleic acids in said sample. 4. The method according to claim 3, wherein said amplifying step is carried out by means of a pair of primers comprising: a first primer complementary to a region of said parkin gene situated 5' of said genetic alteration; and a second primer complementary to a region of said parkin gene situated 3' of said genetic alteration. 5. The method according to claim 1, wherein said sample comprises blood, tissue, plasma or a cell culture from said subject. 6. The method according to claim 3, wherein said sample is pretreated so said parkin gene, or a portion thereof, is accessible for said amplifying step. 7. The method according to claim 1, wherein said detecting is carried out by sequencing, PCR/restriction, ASO, PAGE, or multiplex PCR. 8. The method according to claim 7, wherein said detecting demonstrates deletions of exons, duplications of exons, triplications of exons, or combination thereof. 9. The method of claim 1, wherein said autosomal recessive parkinsonian syndrome is early-onset parkinsonian syndrome, tardive parkinsonian syndrome or atypical parkinsonian syndrome. 10. A method for detecting an autosomal recessive parkinsonian syndrome in a subject comprising analyzing a nucleic acid sample obtained from said subject for the presence of one or more heterozygous genetic alterations in a parkin gene comprising SEQ ID NO:1, wherein said one or more heterozygous genetic alterations in said parkin gene comprises: a) a heterozygous deletion of any one of the following single exons or exon combinations: exons 2 and 3; exon 2; exons 2, 3 and 4; exon 3; exon 5; exons 3-6; exon 6; exons 6-7; exon 8; exons 7, 8, and 9; or exons 3-9; b) a heterozygous duplication of any one of exons 3, 6, 7 or 11, c) a heterozygous point mutation resulting in any one of the following amino acid changes: Gln34Arg; Asn52Met; Lys161Asn; Lys211Asn; Arg256Cys; Arg275Trp; Asp280Asn; Cys268Stop; Cys289Gly; Arg348Glu; Gly328Glu; or Gly430Asp, wherein said amino acid is encoded by SEQ ID NO:1, d) a heterozygous triplication of exon 2, or e) a combination of a)-d) thereof, wherein the presence of one or more heterozygous genetic alterations in said parkin gene indicates that said subject has an autosomal recessive parkinsonian syndrome. 11. The method according to claim 10, wherein said detecting a genetic alteration in said parkin gene comprises isolating nucleic acids from said sample. 12. The method according to claim 10, wherein said detecting a genetic alteration in said parkin gene comprises amplifying nucleic acids in said sample. 13. The method according to claim 12, wherein said amplifying step is carried out by means of a pair of primers comprising: a first primer complementary to a region of said parkin gene situated 5' of said genetic alteration; and a second primer complementary to a region of said parkin gene situated 3' of said genetic alteration. 14. The method according to claim 10, wherein said sample comprises blood, tissue, plasma or a cell culture from said subject. 15. The method according to claim 12, wherein said sample is pretreated so said parkin gene, or a portion thereof, is accessible for said amplifying step. 16. The method according to claim 10, wherein said detecting is carried out by sequencing, PCR/restriction, ASO, PAGE, or multiplex PCR. 17. The method of claim 10, wherein said autosomal recessive parkinsonian syndrome is early-onset parkinsonian syndrome, tardive parkinsonian syndrome or atypical parkinsonian syndrome. 18. A method for detecting an autosomal recessive parkinsonian syndrome in a subject comprising analyzing a nucleic acid sample obtained from said subject for the presence of one or more genetic alterations in a parkin gene comprising SEQ ID NO:1, wherein said one or more genetic alterations in the parkin gene comprises genetic alteration in the heterozygous state, or a genetic alteration in the homozygous state, and wherein the genetic alteration in said parkin gene comprises: a) a deletion of exon 4 or exons 3-4; b) a duplication of exon 3, c) a point mutation resulting in any one of the following amino acid changes: Gln34Arg; or Asn52Met; wherein said amino acid is encoded by SEQ ID NO: 1, d) a triplication of exon 2, or e) a combination of a)-e) thereof, wherein the presence of either one or more heterozygous or homozygous genetic alterations in said parkin gene indicates said subject has an autosomal recessive parkinsonian syndrome. 19. The method according to claim 18, wherein said detecting a genetic alteration in said parkin gene comprises isolating nucleic acids from said sample. 20. The method according to claim 18, wherein said detecting of a genetic alteration in said parkin gene comprises amplifying nucleic acids in said sample. 21. The method according to claim 20, wherein said amplifying step is carried out by means of a pair of primers comprising: a first primer complementary to a region of said parkin gene situated 5' of said genetic alteration; and a second primer complementary to a region of said parkin gene situated 3' of said genetic alteration. 22. The method according to claim 18, wherein said sample comprises blood, tissue, plasma or a cell culture from said subject. 23. The method according to claim 20, wherein said sample is pretreated so said parkin gene, or a portion thereof, is accessible for said amplifying step. 24. The method according to claim 18, wherein said detecting is carried out by sequencing, PCR/restriction, ASO, PAGE, or multiplex PCR. 25. The method of claim 18, wherein said autosomal recessive parkinsonian syndrome is early-onset parkinsonian syndrome, tardive parkinsonian syndrome or atypical parkinsonian syndrome. 26. A method for detecting an autosomal recessive parkinsonian syndrome in a subject comprising analyzing a nucleic acid sample obtained from said subject for the presence of one or more homozygous genetic alterations in said parkin gene comprising SEQ ID NO:1, wherein said detecting a homozygous genetic alteration in said parkin gene comprises: a) a deletion of exons 5 and 6, b) a point mutation resulting in any one of the following amino acid changes: Trp74Cys; Arg334Cys; Thr415Asn; or Trp453Stop, wherein said amino acid is encoded by SEQ ID NO:1, c) a homozygous triplication of exon 2, d) an insertion of GT between nucleotides 321 and 322, e) a deletion of TCTGC in intron 8, or f) a combination of a)-e) thereof, wherein the presence of one or more homozygous genetic alterations in said parkin gene indicates said subject has an autosomal recessive parkinsonian syndrome. 27. The method according to claim 26, wherein said detecting a genetic alteration in said parkin gene comprises isolating nucleic acids from said sample. 28. The method according to claim 26, wherein said detecting a genetic alteration in said parkin gene comprises amplifying nucleic acids in said sample. 29. The method according to claim 28, wherein said amplifying step is carried out by means of a pair of primers comprising: a first primer complementary to a region of said parkin gene situated 5' of said genetic alteration; and a second primer complementary to a region of said parkin gene situated 3' of said genetic alteration. 30. The method according to claim 26, wherein said sample comprises blood, tissue, plasma or a cell culture from said subject. 31. The method according to claim 28, wherein said sample is pretreated so said parkin gene, or a portion thereof, is accessible for said amplifying step. 32. The method according to claim 26, wherein said detecting is carried out by sequencing, PCR/restriction, ASO, PAGE, or multiplex PCR. 33. The method of claim 26, wherein said autosomal recessive parkinsonian syndrome is early-onset parkinsonian syndrome, tardive parkinsonian syndrome or atypical parkinsonian syndrome.

Details for Patent 7,998,667

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2018-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2018-11-19
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2018-11-19